# Rivaroxaban

## XARELTO 15mg

| TAH Drug Code      | [OXAR](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OXAR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. For adult patients with non-valvular atrial fibrillation who have at least one of the following risk factors， rivaroxaban is used to prevent stroke and systemic embolism. Risk factors include heart failure， hypertension， age ?75 years， diabetes， prior stroke， or transient ischemic attack. 2. Rivaroxaban is used for patients at high risk of venous thrombosis (with a history of symptomatic venous thromboembolism) to prevent venous thromboembolism (VTE) following major orthopedic surgery of the lower limbs. 3. For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)， as well as the prevention of recurrent DVT and PE. |
| Dosing             | Prevention of stroke and systemic embolism for patients with non-valvular atrial fibrillation: 15-20mg QD.(Clcr > 50 mL/min). Deep vein thrombosis(DVT)， pulmonary embolism(PE) treatment and prophylaxis: 15mg BID on day 1-21， followed by 20mg QD from day 22. Prophylaxis of VTE high risk patient: 10mg QD.                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Anemia， dizziness， headache， syncope， eye haemorrhage， tachycardia， hypotension， haematoma， epistaxis， GI disorders， pruritus， pain in extremity， urogenital tract haemorrhage， fever， peripheral oedema， decreased general strength & energy， increased transaminases， postprocedural haemorrhage.                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rivaroxaban-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Xarelto 2.5mg

| TAH Drug Code      | [OXAR25](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OXAR25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Cardiovascular event risk; Prophylaxis of Peripheral arterial occlusive disease and Coronary arteriosclerosis， In combination with aspirin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | Prophylaxis of CAD and PAD: 2.5mg BID combined with aspirin 100mg QD. This regimen should not be used when acute thrombosis happened.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Active pathological bleeding. Severe hypersensitivity reaction (eg， anaphylaxis) to rivaroxaban. Patients with severe hepatic impairment or with any degree of hepatic disease associated with coagulopathy. Patients with severe progressive bleeding (such as intracranial hemorrhage， gastrointestinal hemorrhage). PREGNANCY and BREASTFEEDING. Patients with CrCl <15 mL/min.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | >10%: Endocrine & metabolic: Heavy menstrual bleeding (adolescents: 27%) Gastrointestinal: Gastroenteritis (pediatric patients: 13%)， vomiting (pediatric patients: 11% to 14%) Hematologic & oncologic: Hemorrhage (pediatric patients and adults: 5% to 36%; major hemorrhage: <=4%) Respiratory: Cough (pediatric patients: 16%) 1% to 10%: Cardiovascular: Syncope (1%) Dermatologic: Pruritus (2%)， skin blister (1%)， skin rash (pediatric patients: 9%)， wound secretion (3%) Gastrointestinal: Abdominal pain (3%)， gastrointestinal hemorrhage (2%) Hepatic: Increased serum transaminases (>3 x ULN: 2%) Nervous system: Anxiety (1%)， depression (1%)， dizziness (2%)， fatigue (pediatric patients: 7%; adults: 1%)， insomnia (2%) Neuromuscular & skeletal: Back pain (3%)， limb pain (pediatric patients and adults: 2% to 7%)， muscle spasm (1%) <1%: Hematologic & oncologic: Hemophthalmos， surgical bleeding Nervous system: Hemorrhagic stroke， intracranial hemorrhage Postmarketing: Cardiovascular: Cardiac tamponade ， hemopericardium ， thrombosis (with premature discontinuation) Dermatologic: Alopecia ， bullous pemphigoid ， Stevens-Johnson syndrome Endocrine & metabolic: Adrenal hemorrhage (bilateral) Gastrointestinal: Cholestasis Genitourinary: Abnormal uterine bleeding Hematologic & oncologic: Agranulocytosis， retroperitoneal hemorrhage ， splenic rupture ， thrombocytopenia Hepatic: Hepatic failure ， hepatic injury ， hepatitis ， jaundice Hypersensitivity: Anaphylactic shock， anaphylaxis ， angioedema ， drug reaction with eosinophilia and systemic symptoms ， hypersensitivity angiitis ， hypersensitivity reaction Nervous system: Cerebral hemorrhage ， epidural intracranial hemorrhage ， hemiparesis， spinal hematoma Ophthalmic: Vitreous hemorrhage (spontaneous) Renal: Renal disease Respiratory: Bronchiectasis， eosinophilic pneumonitis， pulmonary hemorrhage |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rivaroxaban-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

